Other languages Rezolute, Inc.

Equities

RZLT

US76200L3096

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-06 EDT			5-day change	1st Jan Change
3.27 ^USD	-1.21%		+25.29%	+229.47%

04-18	JonesTrading Starts Rezolute With Buy Rating, $10 Price Target	MT
03-06	Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	03-06
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-13
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	01-23
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema	12-13
Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-13
Rezolute Announces Further Evidence of RZ358?s Efficacy in Tumor-Mediated Hyperinsulinism	23-10-11
Rezolute, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-14
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-09-14
Rezolute to Start Late-Stage Study in Congenital Hyperinsulinism in Europe, Other Places	23-06-27
Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358	23-06-27
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11
Rezolute, Inc. Announces KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema	23-03-23
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-10
Rezolute Initiates Phase 2 Study of Treatment for Diabetic Macular Edema	22-12-15
Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema	22-12-15
Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-09
Rezolute More than Halves Q4 Net Loss	22-09-15
Rezolute, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-15
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	22-09-15
Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer	22-06-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rezolute, Inc.

Equities

RZLT

US76200L3096

Other languages

Filters